The NYTimes has a really interesting article today on real world testing of drugs.  How are consumers to be informed today?  There are limited head to head trials, and almost all of the data comes from highly selected groups of individuals under conditions that are nearly impossible to replicate in the real world.  Ivory tower medicine indeed, giving us the best case scenarios only…but far from the outcome impact for all the spend and utilization occurring in very different ways out in the real world.

Although thousands of medical studies are completed every year, most have relatively limited goals. They often carefully select patients who have few medical problems other than the one under study, making it easier to get one clear result. They may not look at effects over the long term, assuming that if a treatment helps initially, patients will be better off.

But while such studies can help a drug acquire approval or answer a restricted research question, they can leave patients and doctors in a lurch because they may not tell how the new drug or treatment will work once it is tried in real patients with complex problems. Such limited studies, while they can have value, may no longer be enough, particularly when care has become so expensive and real evidence more crucial.

“They are at the heart of why we have trouble making decisions,” said Dr. Scott Ramsey, a professor of medicine at the University of Washington.

continue reading »

 | Posted by Vijay Goel, M.D. | Categories: Uncategorized | Tagged: |

One of the fun things about having a product nearing launch is getting feedback and ideas from really smart folks…and its gratifying to get to a stage where people start seeking where the company could go in a way that I hadn’t even started to think about.

Had a great conversation with Ted Eytan and he shared a few thoughts about our retail, long-tail model on his blog.

Thanks Ted for your thoughts…look forward to sharing the launch soon!

 | Posted by Vijay Goel, M.D. | Categories: Uncategorized | Tagged: |